Pharmacokinetics-pharmacodynamics of antimicrobial therapy: It's not just for mice anymore

被引:556
作者
Ambrose, Paul G.
Bhavnani, Sujata M.
Rubino, Christopher M.
Louie, Arnold
Gumbo, Tawanda
Forrest, Alan
Drusano, George L.
机构
[1] Ordway Res Inst, ICPD, Inst Clin Pharmacodynam, Albany, NY 12208 USA
[2] Ordway Res Inst, Emerging Infect & Fungal Pharmacodynam Lab, Albany, NY 12208 USA
关键词
D O I
10.1086/510079
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Since the advent of the modern era of antimicrobial chemotherapy in the 1930s, animal infection models have allowed for the in vivo evaluation of antimicrobial agents for the treatment of experimentally induced infection. Today, animal pharmacokinetic-pharmacodynamic (PK-PD) infection models serve as a cornerstone of the preclinical assessment process for antibacterial agents and dose and dosing interval selection, as decision support for setting in vitro susceptibility breakpoints, and, finally, for the evaluation of the meaning of in vitro resistance. Over the past 15 years, considerable PK-PD data have been derived from infected patients for many classes of antimicrobial agents. These data provide the opportunity to confirm knowledge gained from animal PK-PD infection models.
引用
收藏
页码:79 / 86
页数:8
相关论文
共 32 条
[1]   Use of pharmacodynamic end points in the evaluation of gatifloxacin for the treatment of acute maxillary sinusitis [J].
Ambrose, PG ;
Anon, JB ;
Owen, JS ;
Van Wart, S ;
McPhee, ME ;
Bhavnani, SM ;
Piedmonte, M ;
Jones, RN .
CLINICAL INFECTIOUS DISEASES, 2004, 38 (11) :1513-1520
[2]   Clinical pharmacodynamics of quinolones [J].
Ambrose, PG ;
Bhavnani, SM ;
Owens, RC .
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 2003, 17 (03) :529-+
[3]   In vivo pharmacodynamics of a new oxazolidinone (linezolid) [J].
Andes, D ;
van Ogtrop, ML ;
Peng, J ;
Craig, WA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (11) :3484-3489
[4]   Pharmacokinetic-pharmacodynamic relationships describing the efficacy of oritavancin in patients with Staphylococcus aureus bacteremia [J].
Bhavnani, SM ;
Passarell, JA ;
Owen, JS ;
Loutit, JS ;
Porter, SB ;
Ambrose, PG .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (03) :994-1000
[5]  
BHAVNANI SM, 2006, 16 EUR C CLIN MICR I, P88
[6]   Application of an in vitro infection model and simulation for reevaluation of fluoroquinolone breakpoints for Salmonella enterica serotype Typhi [J].
Booker, BM ;
Smith, PF ;
Forrest, A ;
Bullock, J ;
Kelchlin, P ;
Bhavnani, SM ;
Jones, RN ;
Ambrose, PG .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (05) :1775-1781
[7]   Pharmacodynamics of oritavancin (LY333328) in a neutropenic-mouse thigh model of Staphylococcus aureus infection [J].
Boylan, CJ ;
Campanale, K ;
Iversen, PW ;
Phillips, DL ;
Zeckel, ML ;
Parr, TR .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (05) :1700-1706
[8]   POSTANTIBIOTIC EFFECT OF IMIPENEM ON PSEUDOMONAS-AERUGINOSA [J].
BUSTAMANTE, CI ;
DRUSANO, GL ;
TATEM, BA ;
STANDIFORD, HC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1984, 26 (05) :678-682
[9]  
Craig W A, 1990, Scand J Infect Dis Suppl, V74, P63
[10]   Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men [J].
Craig, WA .
CLINICAL INFECTIOUS DISEASES, 1998, 26 (01) :1-10